Literature DB >> 21463227

High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.

Rebecka Godtman1, Erik Holmberg, Johan Stranne, Jonas Hugosson.   

Abstract

OBJECTIVE: Recently, the first mortality data from the Göteborg Randomized Population-based Prostate Cancer Screening Trial showed a 44% reduction in prostate cancer (PC)-specific mortality as a result of screening with prostate-specific antigen (PSA). As death of PC is the main endpoint, an accurate determination of the cause of death (COD) is crucial. The aim of this study was therefore to investigate the accuracy of death certificates of men in the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
MATERIAL AND METHODS: Men with a PC diagnosis and who died within the study period (1995-2008) were included. Relevant medical information, including death certificate, was collected. An independent COD committee reviewed the material following a flowchart to classify the COD. The committee's decision was compared with the COD on the death certificate.
RESULTS: Of the 285 men included in the study, 278 men were eligible for a comparative analysis. The committee and the death certificates agreed on PC as the underlying COD in 116 men and causes other than PC in 151. There were 11 discordant cases, for an overall agreement of 96%. Men with PC in the screening group had, compared with the control group, a significantly lower PC-specific mortality but did not differ in non-PC-specific mortality.
CONCLUSION: This study concludes that Swedish death certificates are of high accuracy and can be used for endpoint evaluation in screening studies for PC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463227     DOI: 10.3109/00365599.2011.559950

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  18 in total

1.  Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Authors:  Sigrid Carlsson; Melissa Assel; David Ulmert; Axel Gerdtsson; Jonas Hugosson; Andrew Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2016-04-13       Impact factor: 20.096

2.  Snus use, smoking and survival among prostate cancer patients.

Authors:  Kathryn M Wilson; Sarah C Markt; Fang Fang; Caroline Nordenvall; Jennifer R Rider; Weimin Ye; Hans-Olov Adami; Pär Stattin; Olof Nyrén; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2016-12-15       Impact factor: 7.396

3.  Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden.

Authors:  Ruth Etzioni; Lorelei Mucci; Shu Chen; Jan-Erik Johansson; Katja Fall; Hans-Olov Adami
Journal:  Clin Cancer Res       Date:  2012-08-27       Impact factor: 12.531

4.  Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux.

Authors:  John Maret-Ouda; Karl Wahlin; Hashem B El-Serag; Jesper Lagergren
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

5.  Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.

Authors:  Renata Zelic; Daniela Zugna; Matteo Bottai; Ove Andrén; Jonna Fridfeldt; Jessica Carlsson; Sabina Davidsson; Valentina Fiano; Michelangelo Fiorentino; Francesca Giunchi; Chiara Grasso; Luca Lianas; Cecilia Mascia; Luca Molinaro; Gianluigi Zanetti; Lorenzo Richiardi; Andreas Pettersson; Olof Akre
Journal:  Am J Epidemiol       Date:  2019-06-01       Impact factor: 4.897

6.  Prostate cancer mortality in areas with high and low prostate cancer incidence.

Authors:  Pär Stattin; Sigrid Carlsson; Benny Holmström; Andrew Vickers; Jonas Hugosson; Hans Lilja; Håkan Jonsson
Journal:  J Natl Cancer Inst       Date:  2014-03-07       Impact factor: 13.506

7.  Causes of death in men with localized prostate cancer: a nationwide, population-based study.

Authors:  Mieke Van Hemelrijck; Yasin Folkvaljon; Jan Adolfsson; Olof Akre; Lars Holmberg; Hans Garmo; Pär Stattin
Journal:  BJU Int       Date:  2015-05-15       Impact factor: 5.588

8.  Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Richard Shore; Jingru Yu; Weimin Ye; Jesper Lagergren; Martin Rutegård; Olof Akre; Pär Stattin; Mats Lindblad
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

9.  Population-based study on use of chemotherapy in men with castration resistant prostate cancer.

Authors:  Ingela Franck Lissbrant; Hans Garmo; Anders Widmark; Pär Stattin
Journal:  Acta Oncol       Date:  2013-02-21       Impact factor: 4.089

10.  Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Authors:  Emma L Turner; Chris Metcalfe; Jenny L Donovan; Sian Noble; Jonathan A C Sterne; J Athene Lane; Eleanor I Walsh; Elizabeth M Hill; Liz Down; Yoav Ben-Shlomo; Steven E Oliver; Simon Evans; Peter Brindle; Naomi J Williams; Laura J Hughes; Charlotte F Davies; Siaw Yein Ng; David E Neal; Freddie C Hamdy; Peter Albertsen; Colette M Reid; Jon Oxley; John McFarlane; Mary C Robinson; Jan Adolfsson; Anthony Zietman; Michael Baum; Anthony Koupparis; Richard M Martin
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.